# Twist Bioscience Corp (TWST)

Informational only - not investment advice.

CIK: 0001581280
SIC: 2836 Biological Products, (No Diagnostic Substances)
SIC breadcrumb: [Manufacturing](/division/D/) > [Chemicals And Allied Products](/major-group/28/) > [SIC 2836 Biological Products, (No Diagnostic Substances)](/industry/2836/)
Latest 10-K filed: 2025-11-17
SEC page: https://www.sec.gov/edgar/browse/?CIK=1581280
Filing source: https://www.sec.gov/Archives/edgar/data/1581280/000158128025000025/twst-20250930.htm

## At a glance

FY2025 · period end 2025-09-30 · filed 2025-11-17 · accession 0001581280-25-000025 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001581280.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 376,572,000 USD | 2025 | verified |
| Net income | -77,670,000 USD | 2025 | verified |
| Assets | 641,861,000 USD | 2025 | verified |
| Free cash flow | -75,632,000 USD | 2025 | computed |
| Net margin | -20.63% | 2025 | computed |
| Operating margin | -36.18% | 2025 | computed |
| Revenue YoY | +20.32% | 2025 | computed |
| ROE | -16.42% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

### Peer percentile fingerprint

| Ratio | TWST | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | -20.6% | -14.7% | 47 | 33 |
| Operating margin | -36.2% | -16.8% | 42 | 32 |
| Revenue growth | 20.3% | 20.9% | 49 | 42 |
| FCF margin | -20.1% | -127.6% | 67 | 43 |
| ROE | -16.4% | -38.7% | 78 | 60 |
| ROA | -12.1% | -30.4% | 72 | 66 |
| Liabilities / equity | 0.36 | 0.38 | 46 | 62 |
| Current ratio | 3.64 | 5.52 | 28 | 66 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 2836 Biological Products, (No Diagnostic Substances), not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 376572000 | USD | 2025 | 2025-11-17 |
| Net income | -77670000 | USD | 2025 | 2025-11-17 |
| Assets | 641861000 | USD | 2025 | 2025-11-17 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2025-11-17. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001581280.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue |  | 10,767,000 | 25,427,000 | 54,385,000 | 90,100,000 | 132,333,000 | 203,565,000 | 245,109,000 | 312,974,000 | 376,572,000 |
| Net income |  | -59,310,000 | -71,236,000 | -107,669,000 | -139,931,000 | -152,098,000 | -217,863,000 | -204,618,000 | -208,726,000 | -77,670,000 |
| Operating income |  | -58,482,000 | -70,559,000 | -108,850,000 | -140,079,000 | -152,726,000 | -234,776,000 | -217,159,000 | -220,831,000 | -136,259,000 |
| Diluted EPS |  |  |  |  | -3.57 | -3.15 | -4.04 | -3.60 | -3.60 | -1.30 |
| Operating cash flow |  | -51,301,000 | -66,164,000 | -87,937,000 | -142,255,000 | -112,244,000 | -124,385,000 | -142,474,000 | -64,094,000 | -47,628,000 |
| Capital expenditures |  | 6,594,000 | 3,688,000 | 14,757,000 | 9,868,000 | 27,061,000 | 101,857,000 | 27,779,000 | 5,076,000 | 28,004,000 |
| Assets |  |  | 115,791,000 | 186,994,000 | 398,882,000 | 702,097,000 | 961,378,000 | 776,403,000 | 614,323,000 | 641,861,000 |
| Liabilities |  |  | 26,730,000 | 34,912,000 | 62,620,000 | 121,276,000 | 171,993,000 | 152,971,000 | 141,634,000 | 168,903,000 |
| Stockholders' equity | -76,611,000 | -133,358,000 | -201,422,000 | 152,082,000 | 336,262,000 | 580,821,000 | 789,385,000 | 623,432,000 | 472,689,000 | 472,958,000 |
| Cash and cash equivalents |  | 31,227,000 | 80,757,000 | 46,735,000 | 93,667,000 | 465,829,000 | 378,687,000 | 286,470,000 | 226,316,000 | 183,049,000 |
| Free cash flow |  | -57,895,000 | -69,852,000 | -102,694,000 | -152,123,000 | -139,305,000 | -226,242,000 | -170,253,000 | -69,170,000 | -75,632,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin |  |  |  |  |  | -114.94% | -107.02% | -83.48% | -66.69% | -20.63% |
| Operating margin |  |  |  |  |  | -115.41% | -115.33% | -88.60% | -70.56% | -36.18% |
| Return on equity |  |  |  | -70.80% | -41.61% | -26.19% | -27.60% | -32.82% | -44.16% | -16.42% |
| Return on assets |  |  | -61.52% | -57.58% | -35.08% | -21.66% | -22.66% | -26.35% | -33.98% | -12.10% |
| Liabilities / equity |  |  |  | 0.23 | 0.19 | 0.21 | 0.22 | 0.25 | 0.30 | 0.36 |
| Current ratio |  |  | 5.16 | 5.28 | 9.29 | 8.67 | 6.58 | 5.79 | 4.88 | 3.64 |

## As-reported value updates

No tracked differences above grepcent's stated thresholds and capped precision rule were found between the earliest XBRL-filed value and the value currently on file for the standardized annual metrics grepcent tracks.


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-03. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001581280.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2023-Q1 | 2022-12-31 |  |  | -0.74 | reported discrete quarter |
| 2023-Q2 | 2023-03-31 |  |  | -1.04 | reported discrete quarter |
| 2023-Q3 | 2023-06-30 |  |  | -1.01 | reported discrete quarter |
| 2023-Q4 | 2023-09-30 | 66,946,000 | -46,243,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2023-12-31 | 71,498,000 | -43,008,000 | -0.75 | reported discrete quarter |
| 2024-Q2 | 2024-03-31 | 75,302,000 | -45,492,000 | -0.79 | reported discrete quarter |
| 2024-Q3 | 2024-06-30 | 81,464,000 | -85,571,000 | -1.47 | reported discrete quarter |
| 2024-Q4 | 2024-09-30 | 84,710,000 | -34,655,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2024-12-31 | 88,713,000 | -31,594,000 | -0.53 | reported discrete quarter |
| 2025-Q2 | 2025-03-31 | 92,793,000 | -39,328,000 | -0.66 | reported discrete quarter |
| 2025-Q3 | 2025-06-30 | 96,057,000 | 20,390,000 | 0.33 | reported discrete quarter |
| 2025-Q4 | 2025-09-30 | 99,009,000 | -27,138,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2025-12-31 | 103,698,000 | -30,507,000 | -0.50 | reported discrete quarter |
| 2026-Q2 | 2026-03-31 | 110,715,000 | -44,021,000 | -0.71 | reported discrete quarter |
| 2026-Q3 | 2026-06-30 | 118,376,000 | -35,051,000 | -0.56 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from TWST's latest 10-K: [/company/TWST/business/](/company/TWST/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from TWST's latest 10-K: [/company/TWST/risk-factors/](/company/TWST/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/1581280/000158128026000047/twst-20260630.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Published MD&A gate trimmed front/tail over-capture.
Confidence: high
Filing date: 2026-08-03
Report date: 2026-06-30

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with the unaudited condensed consolidated financial statements and related notes that are included elsewhere in this Form 10-Q and our Annual Report on Form 10-K. This discussion contains forward-looking statements based upon current plans, expectations and beliefs that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, those discussed in the section entitled “Risk Factors” and elsewhere in this Form 10-Q. In preparing this MD&A, we presume that readers have access to and have read the MD&A in our Annual Report on Form 10-K, pursuant to Instruction 2 to paragraph (b) of Item 303 of Regulation S-K.

Overview

We provide customizable solutions across the biological continuum that enable scientific discovery and development across therapeutics, diagnostics, and other high-growth markets. Our proprietary silicon-based platform delivers precision, scale, and speed, supporting consistent, high-quality performance across a broad range of applications.

At the core of our platform is a differentiated method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. By integrating proprietary hardware, software, and scalable infrastructure, including our e-commerce platform, we achieve high levels of precision, automation, and throughput at a lower cost relative to legacy methods.

We have extended this platform beyond DNA synthesis to offer an integrated portfolio that includes synthetic genes, next-generation sequencing, or NGS, applications, sample preparation tools, antibody libraries, and biologics discovery services. These solutions are designed to improve research efficiency, accelerate development timelines, and deliver reproducible, high-quality data. Leveraging the same platform, we also manufacture synthetic RNA, express antibody proteins, perform characterization assays and deliver data to customers and partners.

Our solutions support a wide range of applications, including traditional and AI-enabled therapeutics discovery, diagnostic development, industrial and applied research, agricultural biotechnology, and academic research. By increasing efficiency and scalability in research and development, we support efforts to improve human health and sustainability.

We serve more than 3,800 customers annually across therapeutics, diagnostics, industrial and applied markets, academia, government, and global supply partners. Our multi-channel commercial strategy includes direct sales teams aligned to key markets and an e-commerce platform that enables customers to design, validate, and order customized products on demand, with real-time pricing and order tracking.

We generate revenues primarily from DNA synthesis and protein solutions and NGS applications. As we have expanded from DNA fragments to genes, sample preparation, protein expression, and biologics discovery, the integration of our offerings has strengthened. Beginning in fiscal 2026, we combined synthetic biology tools and biopharma services into a single category, DNA synthesis and protein solutions, and renamed NGS tools to NGS applications to reflect their role in sequencing workflows.

In February 2026, we entered into a license agreement with Invenra Inc. for its proprietary B-Body bispecific antibody discovery platform and simultaneously acquired a 6.24% ownership interest on a fully-diluted basis in Invenra through the purchase of Series B Preferred Stock. Together, these transactions represent a total commitment of $33.8 million, settled through a combination of cash and common stock.

Since our inception, we have incurred net losses each year. Our net loss for the three and nine months ended June 30, 2026 was $35.1 million and $109.6 million, respectively. As of June 30, 2026, we have an accumulated net deficit of $1,429.2 million and cash, cash equivalents and short-term investments of $166.8 million. Our ability to generate product revenues sufficient to achieve profitability will depend heavily on the success of our existing products and the development and commercialization of additional products in the therapeutics, diagnostics, industry and applied, academic research and government, and global supply partners industries as well as leveraging our investment in our manufacturing infrastructure.

In June 2026, we established an at-the-market equity offering program (the "ATM Program") under a Sales Agreement with TD Securities (USA) LLC, as sales agent, pursuant to which we may offer and sell shares of

27

Table of Contents

our common stock having an aggregate offering price of up to $200.0 million from time to time. We are under no obligation to sell any shares under the ATM Program. As of June 30, 2026, no shares had been sold and the full $200.0 million of capacity remained available.

Financial highlights compared to the same periods in the prior fiscal year:

•For the three and nine months ended June 30, 2026, revenues increased 23.2% to $118.4 million and 20% to $332.8 million, respectively, driven by strong performance in DNA synthesis and protein solutions and NGS applications.

•For the three months ended June 30, 2026, gross margin decreased to 52.8% from 53.4% for the same period in the prior year primarily due to customer mix. For the nine months ended June 30, 2026, gross margin increased to 52.1% from 50.5% in the prior year period, primarily due to higher revenues and cost savings realized through continuous process improvement initiatives partially offset by investments for capacity expansion and automation.

•For the three and nine months ended June 30, 2026, loss from operations increased 20.5% to $36.3 million and 8.2% to $115.0 million, respectively, primarily due to an increase in selling, general and administrative expenses and litigation settlement costs, net of recoveries, offset by increases in both revenues and gross profit and a decrease in research and development expenses.

•For the nine months ended June 30, 2026, net cash used in operating activities increased 15.2% to $41.3 million from $35.8 million.

Results of Operations

Comparison of the Three and Nine Months Ended June 30, 2026 and 2025

Revenues

[[GREPCENT_TABLE]]
[["","","Three months ended June 30,","","Nine months ended June 30,"],["(in thousands, except percentages)","","2026","","2025","","Change","","%","","2026","","2025","","Change","","%"],["Revenues","","$","118,376","","","$","96,057","","","$","22,319","","","23","%","","$","332,789","","","$","277,563","","","$","55,226","","","20","%"]]
[[/GREPCENT_TABLE]]

Revenues by Geography

We have one reportable segment from the manufacturing of DNA synthesis and protein solutions and NGS applications products. The following table shows our revenues by geography, based on our customers’ shipping addresses. Americas consists of United States, Canada, Mexico and South America; EMEA consists of Europe, Middle East and Africa; and APAC primarily consists of Japan, China, South Korea, India, Singapore, Malaysia, Australia, New Zealand, Thailand and Taiwan.

[[GREPCENT_TABLE]]
[["","","Three months ended June 30,","","Nine months ended June 30,"],["(in thousands, except percentages)","","2026","","%","","2025","","%","","2026","","%","","2025","","%"],["Americas","","$","77,259","","","65","%","","$","59,387","","","62","%","","$","199,947","","","60","%","","$","168,285","","","61","%"],["EMEA","","33,622","","28","%","","30,742","","32","%","","109,334","","33","%","","89,688","","32","%"],["APAC","","7,495","","7","%","","5,928","","6","%","","23,508","","7","%","","19,590","","7","%"],["Total revenues","","$","118,376","","","100","%","","$","96,057","","","100","%","","$","332,789","","","100","%","","$","277,563","","","100","%"]]
[[/GREPCENT_TABLE]]

Revenues by Products

We historically reported our revenues by the following products: synthetic genes, oligo pools and DNA libraries (collectively, synthetic biology), antibody discovery, and NGS tools. Beginning in fiscal 2026, we combined revenues from synthetic genes, oligo pools, DNA libraries, and biopharma services for antibody discovery into DNA synthesis and protein solutions. We also changed the name of NGS tools to NGS applications, as these

28

Table of Contents

products and services facilitate DNA reading and sequencing workflows. The table below summarizes revenues by the new products:

[[GREPCENT_TABLE]]
[["","","Three months ended June 30,","","Nine months ended June 30,"],["(in thousands, except percentages)","","2026","","%","","2025","","%","","2026","","%","","2025","","%"],["DNA synthesis and protein solutions","","56,571","","","48","%","","40,773","","43","%","","160,905","","","48","%","","122,491","","44","%"],["NGS applications","","61,805","","","52","%","","55,284","","57","%","","171,884","","","52","%","","155,072","","56","%"],["Total revenues","","$","118,376","","","100","%","","$","96,057","","","100","%","","$","332,789","","","100","%","","$","277,563","","","100","%"]]
[[/GREPCENT_TABLE]]

Revenues by Industry

We historically reported revenues by industrial chemicals/materials, academic research, healthcare, and food/agriculture. Beginning in fiscal 2026, we disclose revenues by therapeutics, diagnostics, industry and applied, academic research and government, and global supply partners. These updated categories better align with our operations and increase clarity around our key customer groups. The table below summarizes revenues by industry:

[[GREPCENT_TABLE]]
[["","","Three months ended June 30,","","Nine months ended June 30,"],["(in thousands, except percentages)","","2026","","%","","2025","","%","","2026","","%","","2025","","%"],["Therapeutics","","$","40,413","","","34","%","","$","27,048","","","28","%","","$","118,404","","","36","%","","$","80,070","","","29","%"],["Diagnostics","","43,843","","","37","%","","38,134","","","40","%","","119,118","","","36","%","","108,647","","","39","%"],["Industry and applied","","5,749","","","5","%","","6,105","","","6","%","","17,667","","","5","%","","18,676","","","7","%"],["Academic research and government","","15,512","","","13","%","","11,724","","","12","%","","40,545","","","12","%","","36,589","","","13","%"],["Global supply partners","","12,859","","","11","%","","13,046","","","14","%","","37,055","","","11","%","","33,581","","","12","%"],["Total revenues","","$","118,376","","","100","%","","$","96,057","","","100","%","","$","332,789","","","100","%","","$","277,563","","","100","%"]]
[[/GREPCENT_TABLE]]

Product Shipments

The table below summarizes product shipments:

[[GREPCENT_TABLE]]
[["","","Three months ended June 30,","","Nine months ended June 30,"],["(in thousands)","","2026","","2025","","2026","","2025"],["Number of genes shipped","","369","","237","","940","","669"]]
[[/GREPCENT_TABLE]]

29

Table of Contents

The number of customers who purchased products from us was approximately 2,664 and 2,484 customers for the three months ended June 30, 2026 and June 30, 2025, respectively.

Revenues increased 23% to $118.4 million for the three months ended June 30, 2026, as compared to $96.1 million for the three months ended June 30, 2025. The increase in revenues primarily reflects growth in DNA synthesis and protein solutions revenues of 39% and growth in NGS applications revenues of 12%, both of which are primarily attributable to higher sales to our customers in therapeutics, diagnostics, academic research and government industries, as well as an increase in the number of customers. The number of genes shipped in the three months ended June 30, 2026, increased to approximately 369,000 genes, compared to approximately 237,000 genes in the t

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/1581280/000158128025000025/twst-20250930.htm
Complete FY 2025 MD&A: /company/TWST/mda/fy2025/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Published MD&A gate trimmed front/tail over-capture.
Confidence: high
Filing date: 2025-11-17
Report date: 2025-09-30

Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to promote understanding of the results of operations and financial condition. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes to those statements included elsewhere in this Form 10-K. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results and timing of selected events may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under “Risk Factors” and elsewhere in this Form 10-K. The last day of our fiscal year is September 30, and we refer to our fiscal year ended September 30, 2023 as fiscal year 2023 or 2023, September 30, 2024 as fiscal year 2024 or 2024 and our fiscal year ended September 30, 2025 as fiscal year 2025 or 2025.

Additional information related to the comparison of our results of operations and liquidity and capital resources between the years 2024 and 2023 is included in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations of our Annual Report on Form 10-K for the fiscal year ended September 30, 2024 filed with U.S. Securities and Exchange Commission.

Overview

We are a leading, rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of our platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. We have combined our silicon-based DNA writing technology with proprietary software, scalable commercial infrastructure and an e-commerce platform to create an integrated technology platform that enables us to achieve high levels of quality, precision, automation, and manufacturing throughput at a significantly lower cost than our competitors We have applied our unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing ("NGS"), sample preparation, and antibody libraries for drug discovery and development, all designed to enable our customers to conduct research more efficiently and effectively. Leveraging our same technology, we have expanded our footprint beyond DNA synthesis to manufacture synthetic RNA as well as antibody proteins to disrupt and innovate within larger market opportunities, in addition to discovery partnerships for biologic drugs.

We believe our products enable a broad range of applications that may ultimately improve health and the sustainability of the planet across multiple industries including healthcare, chemicals/materials, food/agriculture, academic research, and technology. We sell our synthetic DNA and synthetic DNA-based products to a customer base of more than 3,800 customers annually across a broad range of industries. In order to address this diverse customer base, we employ a multi-channel strategy comprised of a direct sales force targeting synthetic DNA customers, a direct sales force focusing on the NGS market and an e-commerce platform that serves both commercial channels. We employ business development and sales representatives for our biopharma solutions as well. Our easy-to-use e-commerce platform allows customers to design, validate, and place on-demand orders of customized DNA online, and enables them to receive real-time customized quotes for their products and track their order status through the manufacturing and delivery process. This is a critical part of our strategy to address our large markets and diverse customer base, as well as drive commercial productivity, enhance the customer experience, and promote loyalty.

As we have moved further up the value chain from fragments to genes to preps to proteins and beyond, the strategic connection between our SynBio and Biopharma products tightens. More customers now leverage both products and services to accelerate discovery and identify breakthrough therapeutics. This growing convergence highlights the power of our integrated platform and reinforces Twist’s unique position to serve the full spectrum of innovation in discovery.

We currently generate revenue through our synthetic biology and NGS tools product lines as well as biopharma services for antibody discovery, optimization and development.

We generated revenues of $376.6 million, $313.0 million, and $245.1 million in the years ended September 30, 2025, September 30, 2024, and September 30, 2023, respectively, while incurring net losses of $77.7 million, $208.7 million and $204.6 million in the years ended September 30, 2025, 2024 and 2023, respectively. Since our inception, we have incurred significant operating losses and have accumulated a net deficit of $1,319.6 million. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the success of our existing products and the development and commercialization of additional products in the

47

Table of Contents

synthetic biology and biologic drug industries as well as leveraging our investment in our manufacturing facility in Wilsonville, Oregon.

We sold our DNA data storage business to Atlas Data Storage, Inc. ("Atlas"), a newly formed company, that will focus solely on DNA data storage technology and commercialization, with $155.0 million in seed financing round from third-party investors. The purpose of the transaction was to unlock value by accelerating data storage technology development and allowing each company to focus strategically on its unique products, customers and investors. Under the terms of the contribution agreement executed with Atlas, we assigned and licensed our DNA data storage technology to Atlas in exchange of receiving a minority ownership interest upon close, an upfront cash payment and a secured promissory note. We retained an ownership stake in Atlas and may participate in the upside of DNA data storage through future technology and commercial milestone payments, and a revenue share through royalties on future sales of Atlas’ products and services.

Financial highlights from fiscal year 2025 compared with fiscal year 2024 include:

•Revenue growth of 20% to $376.6 million from $313.0 million, primarily due to growth in NGS tools and synthetic genes;

•Gross margin increased to 50.7% from 42.6%, mainly due to increase in revenues and holding fixed manufacturing costs relatively flat and driving additional cost savings through continuous process improvement initiatives;

•Loss from operations decreased to $(136.3) million from $(220.8) million primarily due to an increase in both revenues and gross profit for the year ended September 30, 2025, and impairment of long-lived assets recognized in the year ended September 30, 2024. Additional contributing factors were a decrease in research and development expenses offset by an increase in selling, general and administrative expenses for the year ended September 30, 2025;

•Net cash used in operating activities for the year ended September 30, 2025 decreased to $47.6 million from $64.1 million for the year ended September 30, 2024; and

•Gain on the sale of DNA digital data storage business of $48.8 million.

See “Results of Operations” below for discussion of our results for the periods presented.

Key Business Metrics

We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. We believe that the following metrics are representative of our current business. However, we anticipate these will change or may be substituted for additional or different metrics as our business grows.

Number of Genes Shipped

We believe that the number of genes shipped serves as a direct indicator of our operational efficiency and market demand. This metric is crucial for assessing our performance in meeting customer demand and generating revenues. Shipments of number of genes in years ended September 30, 2025 and 2024 were as follows:

[[GREPCENT_TABLE]]
[["","","Year ended September 30,"],["(in thousands)","","2025","","2024"],["Number of genes shipped","","938","","","772"]]
[[/GREPCENT_TABLE]]

Number of Customers

We believe that the number of customers who have purchased from us since inception is representative of our ability to drive adoption of our products. We define a customer as a unique "Bill To" account where a single customer may have many "Ship To" locations and may have many unique points of contact within a single "Bill To" customer. In 2025 and 2024, the number of customers who purchased products from us were more than 3,800 and 3,550 customers, respectively.

48

Table of Contents

Percentage of Revenue from Repeat Customers

We believe that the percentage of revenue that we generate from both new and repeat customers is an indicator of our ability to drive adoption of our products amongst existing customers while also generating a robust pipeline of new customers. We define a repeat customer as any customer who has purchased products or services from us more than once in the current fiscal year.

[[GREPCENT_TABLE]]
[["","","Year ended September 30,"],["","","2025","","2024"],["Revenue from repeat customers","","99","%","","98","%"]]
[[/GREPCENT_TABLE]]

Results of Operations

Comparison of the Years Ended September 30, 2025 and 2024

Revenues

We generate revenue from the sales of synthetic biology tools, such as synthetic genes, oligo pools, NGS tools, DNA libraries and biopharma services for antibody discovery, optimization and development. Our ability to increase our revenues will depend on our ability to further penetrate the domestic and international markets, generate sales through our direct sales force, distributors, and over time, from our e-commerce digital platform and the launch of new products.

[[GREPCENT_TABLE]]
[["","","Year ended September 30,"],["(in thousands, except percentages)","","2025","","2024","","Change","","%"],["Revenues","","$","376,572","","$","312,974","","$","63,598","","20%"]]
[[/GREPCENT_TABLE]]

Revenues by Geography

We have one reportable segment from the manufacturing of synthetic DNA products. The following table shows our revenues by geography, based on our customers’ shipping addresses. Americas consists of United States, Canada, Mexico and South America; EMEA consists of Europe, Middle East and Africa; and APAC consists of Japan, China, South Korea, India, Singapore, Malaysia, Australia, New Zealand, Thailand and Taiwan.

[[GREPCENT_TABLE]]
[["","","Year ended September 30,"],["(in thousands, except percentages)","","2025","","%","","2024","","%"],["Americas","","$","225,580","","60%","","$","193,884","","62%"],["EMEA","","124,240","","33%","","92,567","","30%"],["APAC","","26,752","","7%","","26,523","","8%"],["Total revenues","","$","376,572","","100%","","$","312,974","","100%"]]
[[/GREPCENT_TABLE]]

Revenues by Products

The table below sets forth revenues by products:

[[GREPCENT_TABLE]]
[["","","Year ended September 30,"],["(in thousands, except percentages)","","2025","","%","","2024","","%"],["Synthetic genes","","$","113,602","","30%","","$","92,679","","30%"],["Oligo pools","","20,230","","6%","","16,906","","5%"],["DNA libraries","","11,184","","3%","","13,933","","4%"],["Antibody discovery","","23,452","","6%","","20,328","","7%"],["NGS tools","","208,104","","55%","","169,128","","54%"],["Total revenues","","$","376,572","","100%","","$","312,974","","100%"]]
[[/GREPCENT_TABLE]]

49

Table of Conte

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/TWST/mda/fy2025/
All MD&A years: /company/TWST/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/TWST/mda/fy2024/): filed 2024-11-18; accession 0001628280-24-048262 (https://www.sec.gov/Archives/edgar/data/1581280/000162828024048262/twst-20240930.htm)
- [FY 2023 MD&A](/company/TWST/mda/fy2023/): filed 2023-11-21; accession 0001628280-23-039767 (https://www.sec.gov/Archives/edgar/data/1581280/000162828023039767/twst-20230930.htm)
- [FY 2022 MD&A](/company/TWST/mda/fy2022/): filed 2022-11-28; accession 0001628280-22-030817 (https://www.sec.gov/Archives/edgar/data/1581280/000162828022030817/twst-20220930.htm)
- [FY 2021 MD&A](/company/TWST/mda/fy2021/): filed 2021-11-23; accession 0001104659-21-142700 (https://www.sec.gov/Archives/edgar/data/1581280/000110465921142700/twst-20210930x10k.htm)


## FDA-approved drug applications

Applications listed under this company's exact-matched sponsor name. Approved applications only.

No resolved FDA applications were found for this company under the exact-unique, approved-only publish rule.

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

This list covers FDA applications whose listed sponsor name maps to this company by an exact-unique match; applications listed under sponsor names not mapped to this company (subsidiaries, name variants, joint ventures) are absent.


## Macro cross-references

Indicators mapped to this company's SIC classification (industry 2836 Biological Products, (No Diagnostic Substances)) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index
- [TCU](/indicator/TCU/): Capacity Utilization: Total Index
- [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities
- [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity
- [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm

Macro-to-micro threads including this sector: [Inflation (CPI / PCE / PPI)](/thread/inflation-cpi-pce-ppi/), [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/TWST.md · JSON record: /company/TWST.json · verified financials: /company/TWST/financials.json / /company/TWST/financials.csv · machine TOC for the whole site: /llms.txt